Clinical Trial Update: ONO-4538 Phase I Study in Patients With Solid Tumor [Phase 1]

View source ↗

Summary

Phase I study of ONO-4538 (nivolumab) in patients with solid tumors has completed. The sponsor is Ono Pharmaceutical Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ONO-4538

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Advanced Solid Tumors, Recurrent Solid Tumors | Phase 1 | Status: COMPLETED